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Letters to the Editor
COMMENTS ON "THE SCM TEST FOR CANCER. AN EVALUATION IN TERMS
OF LYMPHOCYTES FROM HEALTHY DONORS AND CANCER PATIENTS"
by MITCHELL, WOOD, PENTYCROSS AND BAGSHAWE
(Br. J. Cancer (1980) 41, 772)
SIR,-In their paper Mitchell et al. give the
impression that having established the SCM
technique in their laboratory, an evaluation
of the SCM test for cancer was conducted.
However, the analysis of their paper reveals
that the SCM technique was not well estab-
lished. The 2 major faults in their procedures
were that the polarization measurements
were fraught with stray-light artefacts and
that they did not succeed in isolating the
density-specific subpopulations of lympho-
cytes required for the successful acomplish-
ment of the SCM test.
(1) It has been shown before (Cercek, 1980)
that an asymptotic decrease in P values with
increasing time of incubation of lymphocytes
in the FDA substrate, indicates a stray-light
artefact. Since the "idealized" results of
Mitchell et al., delineated in their Fig. 3, show
an asymptotic dependence of polarization on
time of FDA hydrolysis, it follows that their
results with the MPF-4 instrument were
fraught with stray-light artefacts. Further-
more, their results with a "direct polarization
instrument" contradict their results with the
MPF-4 instrument, as stated: "Results ob-
tained on the direct polarization instrument
showed P to remain constant for several
minutes at the start of reaction. ." If the
results in Fig. 3 were correct and artefact-
free, according to Weber's addition law of
polarizations (Weber, 1952) the "direct
polarization instrument" should have also
recorded a fast initial deciease in P, and not
as they stated a constant value for several
minutes at the start of the FAD-hydrolysis
reaction. However, the direct polarization
instrument data agree with our own artefact-
free results, which show that P remains
practically constant, i.e. decreases by
only 0.36%/min (Cercek, 1980), leading to
a decrease of only 1% over a period of 3
min, which is well within the experimental
error of +2.5%. A stray-light artefact affects
the SCM test results as follows: In lymph-
ocytes incubated with PHA, or some
antigen preparations, the rate of FDA
hydrolysis is decreased (Cercek et al., 1980).
To obtain an 80-90% deflection on the re-
corderwithin a similartimeofFDAhydrolysis
in both control and stimulated samples, an
electronic amplification is required during
measurements of stimulated samples. Since
the stray-light artefact is highly polarized
and its magnitude is proportional to ampli-
fication, the artefactual increase in P
counteracts the intracellular decrease ob-
served on stimulation, causing abrogation or
underestimation of lymphocyte responses.
Therefore, even ifthe correct SCM-responding
subpopulation of lymphocytes had been
isolated, smaller or insignificant decreases in
P would have been seen on stimulation.
(2) Successful accomplishment of the SCM
test depends upon the isolation of a density-
specific subpopulation of lymphocytes which
consists ofover 75% ofT-type cells (Cercek &
Cercek, 1978a; Pritchard et al., 1978). That
SCM-responders belong within the T cells has
been shown by 0rjasaeter et al. (1979). In
contrast, Mitchell et al. evaluated the SCM
test on lymphocyte subpopulations containing
only30-53% ofT cells. It is obvious that they
did not succeed in reproducing the experi-
mental conditions required for the isolation
of the correct SCM-responding population.
This is also evident from their statement that
no emission polarization peak was seen at
510 nm in the upper-layer lymphocytes
(Cercek & Cercek, 1977; 1978b). We also
have to point out that their mean P for
control lymphocytes is not within one
standard deviation of our values. (In the
standard errors cited (Cercek & Cercek, 1977;
1978b) the decimal points are misplaced. The
correct s.e. for healthy controls is +0 0004
and that for cancer patients +0 0003, for
which we apologise.) That control P values
are not as low as those given by Mitchell et al.
can also be seen from our report thatP values948 LETTERS TO THE EDITOR
ofSCM-responding lymphocytes are normally
higher than 0-185 (Cercek & Cercek, 1978b).
Hence, their low control P values again indi-
cate an incorrect population of lymphocytes.
It is not, therefore, surprising that they were
unable to obtain as good a differentiation
between normal subjects and cancer patients
as reported by us (Cercek et al., 1974; Cercek
& Cercek, 1977; 1978b) and other laboratories
which confirmed the SCM test (Takaku et al.,
1977; Hashimoto et al., 1978; Kreutzman et
al., 1978; Pritchard & Sutherland, 1978;
Pritchard et al., 1978; 0rjasaeter et al., 1979).
Furthermore, we have recently conducted a
well documented blind study in which instead
of the general-pool "cancer basic proteins"
the synthetic encephalitogenic nanopeptide,
EF (Beckman Inc.) was used. The results
were evaluated both as the "SCM-Response-
Ratio", RRsCM=PEF/PPHA (Cercek et al.,
1974) and as the "SCM-Index" (Pritchard et
al., 1978). The results obtained on 51 cancer
patients and donors with non-malignant
diseases were found to agree in 88% of the
cases with the current medical diagnosis. The
9% statistical confidence limits encompass
score rates published by us and other labora-
tories which confirmed the SCM test.
It follows that in laboratories in which the
technique is well established, the resolution
between patients with cancer and those with
non-cancerous diseases or healthy donors is
better, and the score rates are well above that
reported by Mitchell et al.
We would also like to point out that
Mitchell et al. present a very biased view of
the development of the SCM test. In 1974,
when we first reported on the possibility of a
biophysical differentiation of lymphocytes
from cancer patients, healthy donors and
patients with non-cancerous diseases (Cercek
et al., 1974) the underlying biological mech-
anisms of the "SCM-phenomenon" were not
then known. It was obvious that the observed
phenomenon needed clarification and more
research, and qualifications of the limiting
conditions for the SCM-test technique were
outstanding. We have, therefore, investigated
several different parameters which could
affect the results of the SCM test (Cercek &
Cercek, 1976; 1977; 1978a) and have also
endeavoured to elucidate the phenomenon of
changes in SCM (Cercek et al., 1978; Cercek &
Cercek, 1979). Laboratories which have con-
firmed the SCM test and were genuinely inter-
ested in this developing technique were in
contact with us and did not find it difficult to
assimilate the new findings. On the contrary,
after establishing the SCM measurements,
some ofthe laboratories introduced their own
modifications of the test (Pritchard et al.,
1978; 0rjasaeter et al., 1979). It follows that
the results of Mitchell et al. do not represent
an evaluation of the SCM test, but only
demonstrate that they did not succeed in
establishing the SCM technique in their
laboratory.
18 August 1980
L. CERCEK AND B. CERCEK
Paterson Laboratories, Christie Hospital and
Holt Radium Institute, Manchester
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SIR,-We thank Drs L. & B. Cercek for
their comments. It is, we agree, debatable
whether we established "the SCM test",
though 12 man-years were spent trying to
establish it by following the described pro-
cedures; an unlikely indulgence had our
motivation been bias.
Lymphocyte preparation was performed as
described and 2 distinct layers were obtained
in - 70% ofoccasions. As indicated in Tables
II, III and IV of our paper, 92-99%/' of the
upper-layer cells were lymphocytes with T:B
ratio ofthe order of4:1, so that , 75% ofthe
upper layer were T cells. The rosetting tech-
niques we used required 4 sheep erythrocytes
to attach to the lymphocytes, and this may
have underestimated the T-cell population by
more recent criteria.
Cercek & Cercek cite 0rjasaeter et al. (1979)
as demonstrating that T cells are the re-
sponders in the SCM test, but we note that
these authors used a pure T-cell suspension
obtained by a different method, because "the
separation procedure of Cercek & Cercek
(1977) gave inconsistent results in our hands".
On the question ofstray-light artefacts it is
appropriate to point out that the MPF-4
instrument we used was the one on which the
Cerceks successfully demonstrated themethod
at the 1976 Charing Cross Workshop.
The fact is that we have not been able to
substantiate the original claim for a cancer
test with the high order ofreliability required
for clinical usefulness. Nor, it seems, are we
alone, since the 565/575 correct diagnoses
reported by Cercek & Cercek (1977) with a
method that needed "clarification and more
research" is now supported after much fur-
ther research by 88% correct results on 51
patients in a study with an unpublished
protocol. We are also unaware of any other
laboratory reporting significant results with
the SCM procedure in its original or modified
(1977) form.
11 September 1980
K. D. BAGSHAWE
C. R. PENTYCROSS
H. MITCHELL
Department ofMedical Oncology, Charing Cross
Hospital Medical School, London